Skip to main content

Table 5 COOP scores.

From: S-Adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: A double-blind cross-over trial. [ISRCTN36233495]

   Baseline SAMe Celecoxib  
Variable N+ Mean (SD) Mean (SD) Mean (SD) Stdif.
Total Score 46 48.7 (8.7) 39.9* (9.3) 39.8* (11.3) -0.01
Physical Condition 46 56.2 (20.4) 51.7 (19.1) 51.3 (18.2) -0.02
Emotional Condition 46 37.6 (16.1) 33.5 (17.9) 34.8 (17.6) 0.07
Daily Work 46 47.1 (17.0) 34.3* (14.4) 33.9* (15.7) -0.03
Social Activities 46 31.4 (15.4) 29.1 (13.1) 29.6 (15.6) 0.02
Pain 46 70.5 (14.1) 53.0* (15.9) 50.9* (19.2) -0.10
Change in Condition 46 65.2 (13.3) 49.1* (16.7) 47.8* (18.6) -0.05
Overall Condition 46 50.0 (16.1) 44.3* (16.3) 41.3* (16.0) -0.19
Social Support 46 39.0 (24.6) 29.6* (18.3) 32.6 (18.1) 0.17
Quality of Life 46 41.0 (13.9) 34.3* (16.1) 36.1 (13.1) 0.11
  1. Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe +Sample sizes are less than 57 due to missing data in either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). No statistically significant differences were observed between SAMe and Celecoxib